This article compares published clinical trial data from separate studies. Cross-trial comparisons carry inherent limitations due to differences in population, study design, and duration. This is educational content only — not a recommendation for any specific drug or treatment plan.

⚠ Investigational Drug — Not FDA-Approved

Retatrutide is not FDA-approved as of June 2026. Tirzepatide (Zepbound) is FDA-approved for chronic weight management. Cross-trial comparisons in this article are approximate and should not be used to make individual prescribing decisions. The TRIUMPH-5 head-to-head trial is the only source that will provide a methodologically clean comparison.

The central question in obesity pharmacology in 2026 is whether retatrutide's Phase 3 results represent a genuine advance over tirzepatide or whether the headline numbers reflect trial design differences. This article examines both questions in detail: what the numbers actually show, what the methodological limitations are, and what remains to be proven.

For general background on the retatrutide trial results, see our article on retatrutide weight loss results. For the mechanistic explanation of why a triple agonist should produce more weight loss than a dual agonist, see our article on triple agonist weight loss drugs.

The Trial Data: SURMOUNT-1 vs. TRIUMPH-1

SURMOUNT-1 (Tirzepatide)

SURMOUNT-1, published in the NEJM in 2022, was the pivotal Phase 3 obesity trial for tirzepatide. Key details:

  • Population: 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities) and without type 2 diabetes
  • Duration: 72 weeks
  • Mean baseline weight: approximately 231 lbs (104.8 kg)
  • Mean baseline BMI: approximately 38
  • Doses studied: 5 mg, 10 mg, 15 mg (plus placebo)
  • Primary endpoint: Percentage change in body weight from baseline at 72 weeks

Results at 72 weeks (maximum dose: 15 mg):

  • Mean weight loss at 15 mg: 20.9% (~21.8 kg / 48 lbs)
  • Mean weight loss at 10 mg: ~19.5%
  • Mean weight loss at 5 mg: ~15.0%
  • Placebo: ~3.1%
  • Participants achieving ≥20% weight loss at 15 mg: approximately 57%
  • Participants achieving ≥25% weight loss at 15 mg: approximately 36%
  • Participants achieving ≥30% weight loss at 15 mg: approximately 28%

TRIUMPH-1 (Retatrutide)

TRIUMPH-1 topline results were reported May 21, 2026, with full data presented at ADA 2026 on June 6, 2026. Key details:

  • Population: 2,339 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities) and without type 2 diabetes
  • Duration: 80 weeks (plus a 104-week blinded extension in the high-BMI subgroup)
  • Mean baseline weight: approximately 248.5 lbs (112.7 kg)
  • Mean baseline BMI: approximately 40.0
  • Doses studied: 4 mg, 9 mg, 12 mg (plus placebo)
  • Primary endpoint: Percentage change in body weight from baseline at 80 weeks

Results at 80 weeks (maximum dose: 12 mg):

  • Mean weight loss at 12 mg: 28.3% (~70.3 lbs from 248.5 lb baseline)
  • Mean weight loss at 9 mg: 25.9% (~64.4 lbs)
  • Mean weight loss at 4 mg: 19.0% (~47.2 lbs)
  • Placebo: 2.2%
  • Participants achieving ≥25% weight loss at 12 mg: 62.5%
  • Participants achieving ≥30% weight loss at 12 mg: 45.3%
  • Participants achieving ≥35% weight loss at 12 mg: 27.2%

Methodological Differences: What Complicates Direct Comparison

1. Different Endpoint Duration (72 vs. 80 Weeks)

TRIUMPH-1's primary endpoint was at 80 weeks — 8 weeks longer than SURMOUNT-1's 72 weeks. For drugs in this class, additional treatment time produces additional weight loss. How much does 8 weeks matter?

The additional weight loss from weeks 72 to 80 in TRIUMPH-1 can be estimated from the Phase 2 dose-response curve and the Phase 3 trajectory. Based on the weight-loss rate in the late portion of the TRIUMPH-1 trial (which was still descending, not plateau), the incremental 8-week contribution to the 28.3% result is estimated at approximately 1–2 percentage points. Even after accounting for this, the adjusted retatrutide advantage at a matched 72-week endpoint remains approximately 5–6 percentage points above tirzepatide — still a substantial and clinically meaningful difference.

2. Different Baseline Body Weight

TRIUMPH-1 participants had a higher mean baseline weight (112.7 kg / 248.5 lbs) compared to SURMOUNT-1 participants (~104.8 kg / 231 lbs). People with higher absolute body weight at baseline tend to lose more absolute weight, but percentage-based endpoints partially normalize this. The 8 kg difference in mean baseline weight may contribute marginally to the percentage-loss difference but is unlikely to explain more than 1–2 percentage points of the 7–8 percentage point gap between trials.

3. Different Dose Ranges

Tirzepatide's maximum tested dose in SURMOUNT-1 was 15 mg. Retatrutide's maximum in TRIUMPH-1 was 12 mg. The doses are not directly comparable because the drugs operate through different receptors — comparing 12 mg retatrutide to 15 mg tirzepatide is not a milligram-for-milligram comparison. The relevant question is maximum approved dose performance, not dose equivalence, and on that metric retatrutide's best result (28.3% at 12 mg) significantly exceeds tirzepatide's best result (20.9% at 15 mg).

4. Statistical Analysis Populations

TRIUMPH-1 results were reported as the "efficacy estimand" (as-treated, accounting for treatment discontinuation). SURMOUNT-1 used multiple estimands. The specific estimand used can affect the magnitude of the reported mean — typically by 1–3 percentage points. Full data from TRIUMPH-1's peer-reviewed publication (not yet available as of June 2026 — full data was presented at ADA but not yet in print) will clarify the estimand comparison.

The Phase 2 Comparison: Earlier Evidence for the Gap

The efficacy advantage for retatrutide was visible at the Phase 2 stage:

  • Retatrutide Phase 2 (NEJM 2023): 24.2% weight loss at 48 weeks at the 12 mg dose
  • Tirzepatide Phase 2 (NEJM 2021): approximately 14.7% weight loss at 36 weeks at the maximum tested dose

These are at different timepoints, but the magnitude of the difference — roughly 10 percentage points even accounting for endpoint differences — is consistent with the Phase 3 gap of approximately 7–8 percentage points. The Phase 2 and Phase 3 data together form a consistent pattern that is unlikely to be explained purely by methodological differences.

The Lower-Dose Comparison: A Cleaner Signal

One way to partially control for the maximum-dose comparison issue is to look at lower-dose results, which are available at more comparable dose levels:

  • Tirzepatide 5 mg, 72 weeks: approximately 15.0% weight loss
  • Retatrutide 4 mg, 80 weeks: 19.0% weight loss

At the lowest studied maintenance doses, retatrutide outperforms tirzepatide by approximately 4 percentage points over a similar timeframe. This lower-dose comparison is subject to fewer confounders than the maximum-dose comparison, and the advantage persists. This suggests the efficacy gap is not solely a maximum-dose effect but reflects the fundamental mechanistic advantage of triple over dual agonism across the dose range.

The 30% Responder Analysis: The Most Clinically Meaningful Difference

The proportion of patients achieving at least 30% weight loss — the threshold associated with bariatric surgery outcomes — is one of the most clinically significant differences between the two drugs:

  • Tirzepatide 15 mg (SURMOUNT-1): approximately 28% achieved ≥30% weight loss at 72 weeks
  • Retatrutide 12 mg (TRIUMPH-1): 45.3% achieved ≥30% weight loss at 80 weeks

Even with an 8-week endpoint advantage, the nearly 17 percentage point difference in 30% responders is striking. For patients whose clinical goals require reaching the bariatric-surgery efficacy zone (30%+ loss), retatrutide's data suggests this is achievable in nearly half of all patients — roughly double the rate with tirzepatide.

TRIUMPH-5: The Head-to-Head Trial That Will Settle the Question

TRIUMPH-5 is a Phase 3, randomized, double-blind trial directly comparing retatrutide against tirzepatide in adults with obesity. It is actively enrolling as of June 2026, with primary results expected approximately December 2026.

This trial will:

  • Randomize participants to retatrutide versus tirzepatide under the same protocol, eliminating population and design confounders
  • Use a pre-specified head-to-head endpoint that will establish whether the observed cross-trial gap is a real efficacy difference
  • Provide safety comparison data under comparable conditions
  • Be the data that both FDA reviewers and payers will use to assess retatrutide's value relative to an already-available alternative

Until TRIUMPH-5 data is available, the cross-trial comparison presented in this article represents the best available evidence — directionally consistent and likely real, but not definitive.

What the Safety Comparison Adds to the Efficacy Picture

A comparison of weight loss results alone does not tell the complete clinical story. Safety comparison is essential:

Tirzepatide (SURMOUNT-1, 15 mg):

  • Discontinuation due to adverse events: approximately 6.3% at 15 mg
  • Nausea: ~25–31% at 15 mg
  • Diarrhea: ~15–20% at 15 mg
  • No dysesthesia signal
  • No UTI signal above placebo

Retatrutide (TRIUMPH-1, 12 mg):

  • Discontinuation due to adverse events: 11.3% at 12 mg (4.1% at 4 mg — below placebo)
  • Nausea: 42.4% at 12 mg
  • Diarrhea: 32.0% at 12 mg
  • Dysesthesia: ~12.5% at 12 mg (unique to retatrutide)
  • UTI: 7.5–8.8% vs. 5.3% on placebo

At the highest doses, retatrutide has higher GI event rates and nearly double the discontinuation rate compared to tirzepatide. For patients who can tolerate the higher burden, the additional 7+ percentage points of weight loss may be worth it. For patients who cannot, the 4 mg dose offers 19% weight loss with excellent tolerability — comparable to tirzepatide's efficacy with better tolerability.

This tolerability-efficacy spectrum is the key clinical decision framework for when retatrutide becomes available. For an explanation of why these side effects occur and how titration manages them, see our article on retatrutide titration schedule.

The Practical Reality: Tirzepatide Is Available Now

For patients seeking the best available obesity pharmacotherapy today, this comparison has a simple practical answer: tirzepatide (Zepbound) is approved, available by prescription, and covered by many insurance plans. Retatrutide is not available and will not be for at least 12–18 months.

The opportunity cost of waiting for retatrutide while untreated is significant. A patient who begins Zepbound today and achieves 20% weight loss will have substantially better metabolic, cardiovascular, and quality-of-life outcomes over the next 18 months than a patient who waits. If retatrutide achieves approval in late 2027, that patient can then discuss with their physician whether transitioning is appropriate based on their clinical goals and response to tirzepatide.

For patients who need more than the ~20% available from tirzepatide — specifically those with severe obesity (BMI ≥45), those who have reached a plateau on tirzepatide, or those for whom achieving bariatric-surgery-level weight loss is necessary for disease management — the retatrutide efficacy data is genuinely consequential and worth waiting for in clinical discussion with their physician.

For timeline information on when retatrutide becomes available, see our retatrutide FDA approval date article. For information about Mounjaro (tirzepatide) in the T2D context specifically, see retatrutide vs. Mounjaro.

Independent Analysis: Three Observations About This Comparison

The tirzepatide vs. retatrutide comparison carries implications beyond the headline numbers that deserve attention:

1. The incremental jump from tirzepatide to retatrutide is larger than the jump from semaglutide to tirzepatide

When tirzepatide's Phase 3 data was published, it showed approximately a 6 percentage point advantage over semaglutide (20.9% vs. approximately 15%). Retatrutide's TRIUMPH-1 shows approximately a 7–8 percentage point advantage over tirzepatide in Phase 3 — meaningfully larger in absolute terms. Each generation of obesity drugs since semaglutide has delivered a larger step-change improvement than its predecessor, a pattern that, if continued, would imply that obesity pharmacotherapy is still far from its ceiling.

2. Patient expectations need recalibration across drug generations

Clinicians currently prescribing tirzepatide help patients set expectations around 15–21% weight loss as the pharmacological range. When retatrutide launches, those expectations will need to be updated for patients who ask "why didn't my previous doctor prescribe the one that causes 28% loss?" The answer — that retatrutide was not yet approved during earlier prescribing — will require clear, patient-facing communication about the difference between available and investigational therapies, and why the timeline exists. Publishers like GLPTree have a role in helping patients understand this distinction proactively.

3. The real-world efficacy gap may be smaller than the trial gap

Clinical trial populations are carefully selected, highly motivated, and monitored closely. Real-world outcomes on any drug are typically 20–30% lower in absolute weight loss than trial outcomes. Retatrutide's higher discontinuation rate at 12 mg (11.3% vs. tirzepatide's ~6%) means that in real-world prescribing, where dose escalation may be less structured and monitoring less intensive, a larger proportion of patients will settle at lower doses or discontinue. The real-world average outcome for retatrutide may be closer to 20–23% rather than the 28.3% trial number, while tirzepatide's real-world average (already validated through two-plus years of prescribing experience) is approximately 15–18%. The gap likely narrows in practice but does not close.

Frequently Asked Questions

Does retatrutide cause more weight loss than tirzepatide?

Based on separate Phase 3 trials in comparable populations, retatrutide produced 28.3% average weight loss at 80 weeks versus tirzepatide's 20.9% at 72 weeks. The ~7–8 point gap is too large to be fully explained by the 8-week endpoint difference. No direct head-to-head trial has been published yet — TRIUMPH-5 results are expected December 2026.

What were tirzepatide's weight loss results in SURMOUNT-1?

In SURMOUNT-1 (2,539 adults with obesity without T2D, 72 weeks), tirzepatide at 15 mg produced 20.9% average weight loss (~48 lbs). At 10 mg: ~19.5%. At 5 mg: ~15.0%. About 28% of 15 mg participants achieved ≥30% weight loss.

What were retatrutide's weight loss results in TRIUMPH-1?

In TRIUMPH-1 (2,339 adults with obesity without T2D, 80 weeks), retatrutide at 12 mg produced 28.3% average weight loss (~70.3 lbs). At 9 mg: 25.9%. At 4 mg: 19.0%. 45.3% of 12 mg participants achieved ≥30% weight loss. A 104-week extension in the high-BMI subgroup reached 30.3%.

Why do obesity drug trials use different endpoints?

Sponsors choose endpoints capturing sufficient weight loss to demonstrate efficacy. SURMOUNT-1 used 72 weeks; TRIUMPH-1 used 80 weeks based on Phase 2 showing retatrutide's curves had not plateaued at 48 weeks. The 8-week difference partially explains the gap but cannot account for the full 7–8 percentage point advantage.

What is TRIUMPH-5 and when will it report?

TRIUMPH-5 is a Phase 3 head-to-head randomized trial directly comparing retatrutide vs. tirzepatide, actively enrolling as of June 2026 with results expected approximately December 2026. It will provide the first clean, controlled comparison between the two drugs.

Can I switch from tirzepatide to retatrutide?

Retatrutide is not yet approved, so switching is not currently possible outside of a clinical trial. When approved (expected late 2027), the transition would be a clinical decision made with a prescriber based on individual response, goals, and tolerability. No transition data currently exists.

What is the weight loss difference at the lowest trial doses?

Tirzepatide 5 mg produced approximately 15% at 72 weeks in SURMOUNT-1. Retatrutide 4 mg produced 19.0% at 80 weeks in TRIUMPH-1. The lower-dose advantage favors retatrutide even at comparable dose levels — and the 4 mg dose had better tolerability than any tirzepatide dose (4.1% discontinuation vs. placebo's 4.9%).

Sources

  1. Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial." NEJM, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
  2. Wilding JPH, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." NEJM, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  3. Eli Lilly. TRIUMPH-1 Phase 3 Topline Results. May 21, 2026. Tech Times coverage: https://www.techtimes.com/articles/317019/20260522/eli-lillys-retatrutide-matches-bariatric-surgery-30-weight-loss-phase-3-trial.htm
  4. Pharmaceutical Technology. ADA 2026 TRIUMPH-1 full data presentation coverage. June 18, 2026. https://www.pharmaceutical-technology.com/analyst-comment/ada26-retatrutide-unprecedented-weight-loss-phase-iii-triumph-1/
  5. STAT News. "Lilly shares safety, tolerability data on its next-gen obesity drug." ADA 2026, June 6, 2026. https://www.statnews.com/2026/06/06/illy-retatrutide-triple-g-weight-loss-obesity-safety-data-ada/
  6. ClinicalTrials.gov. TRIUMPH-1, NCT05929066. https://clinicaltrials.gov/study/NCT05929066